Humana's margins have declined due to rising policy benefits, high medical loss ratios, and increased utilization ...
Boston Scientific is a Buy with a $109 target and 14% upside from strong demand, Q3 beats, raised FY25 guidance, and growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback